Abstract: The present disclosure relates to novel two-dimensional halide perovskite materials, and the method of making and using the two-dimensional halide perovskite materials.

Abstract: The present invention relates to a new family of titanium heterometallic structured metal-organic materials (MOFs) having, among other characteristics, high porosity, stability in an aqueous medium and photocatalytic activity under visible light and UV radiation. The new family of materials has a structural unit that combines tetravalent titanium with multiple combinations of divalent metals with a homogeneous distribution at atomic level in the MOF structure. The invention also relates to methods for obtaining them with high yields, in addition to their uses in the generation of solar fuels, photoactivated degradation, photoreduction of CO2, heterogeneous catalysis, as a component or part of an electronic component and/or as a porous or photoactive coating for controlling pollutants, inter alia.

Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.

Abstract: Lactivicin compounds of formula (I) and pharmaceutically acceptable salts of the compounds of formula (I) are provided, wherein the compounds comprise antibiotics suitable for use either alone or in combination with ?-lactamase inhibitors and/or other antibiotics (including ?-lactam and non-?-lactam antibiotics) in the treatment or prevention of bacterial infections.

Abstract: This document relates to functionalized (e.g., mono- or bi-functional) polymers (e.g., polyethylene glycol and related polymers) as well as methods and materials for making and using such functionalized polymers.

Abstract: Provided is a method of stabilizing a perfluorodioxolane compound, which includes having a quinone compound present in a composition containing a perfluorodioxolane compound, wherein the perfluorodioxolane compound is one or more perfluorodioxolane compounds selected from the group consisting of a perfluorodioxolane compound denoted by general formula (1) and a perfluorodioxolane compound denoted by general formula (2).

Abstract: Disclosed are solid state forms of lumateperone ditosylate, uses thereof, and pharmaceutical compositions thereof.

Abstract: A binuclear Fe(III) fused porphyrin. Synthesizing the binuclear fused porphyrin includes combining free-base fused-porphyrin and a solvent to yield a solution, refluxing the solution, combining a metal salt with the solution, and removing the solvent from the solution.

Abstract: Described herein, inter alia, are compositions and methods for treating or preventing obesity and using the same.

Abstract: The present disclosure provides creatine prodrug analogs and their compositions useful for the treatment of creatine deficiencies.

Abstract: Disclosed herein are methods of treating or suppressing a disorder selected from the group consisting of ?-synucleinopathies, tauopathies, ALS, traumatic brain injury, and ischemic-reperfusion related injuries.ury, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the formula: or the hydroquinone form thereof; or a solvate or hydrate thereof.

Abstract: A coloring composition includes a metal azo pigment, a compound having an ethylenically unsaturated bonding group, and a solvent, the metal azo pigment includes at least one kind of an anion selected from an azo compound represented by Formula (I) or an azo compound having a tautomeric structure of the azo compound represented by Formula (I), two or more kinds of metal ions, and a melamine compound, and in Formula (I), R1 and R2 each independently represent OH or NR5R6, R3 and R4 each independently represent ?O or ?NR7, and R5 to R7 each independently represent a hydrogen atom or an alkyl group.

Abstract: Provided herein are compounds, compositions, and methods useful for the treatment of breast cancer, particularly triple negative breast cancers. In certain aspects, provided herein are compounds of formula (I): or a pharmaceutically acceptable salt or solvate thereof. In certain aspects, provided herein are compositions comprising any of the compounds provided herein. In certain aspects, provided herein are methods for the treatment of cancer in a subject in need thereof comprising administering to the subject an effective amount of any of the compounds or compositions provided herein.

Abstract: The invention provides novel polymer-protein conjugates and molecular assemblies for controlled intracellular delivery of proteins, and compositions and methods of preparation and use thereof.

Abstract: Disclosed is a compound of formula (I) in which R1, R2, and R3 are as described herein. Also provided are pharmaceutical compositions comprising the compound of formula (I) and methods of using the compound of formula (I), including a method of treating a disease or disorder and a method for effectuating a G-protein coupled receptor (GPCR)-mediated response in a subject.

Abstract: The invention discloses a method for fluoroalkylation of enamines with a fluoro alkyl halide in the presence of a base.

Abstract: The present disclosure relates to a coating composition and an organic light emitting device.

Abstract: The present application provides malonamide compounds, and derivatives thereof (e.g., N-aryl malonamides (NAM), acetamides, oxalamides, and the like), that are useful, for example, for the treatment of acute, chronic/persistent, and/or relapsing infections. Pharmaceutical compositions, methods of treating diseases (e.g., bacterial infections), and methods of reducing bacterial virulence are also provided.

Abstract: There are provided compounds of Formula I, and pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions thereof, used for inhibition or modulation of the activity of cyclin dependent kinases (CDK) and/or glycogen synthase kinase-3 (GSK-3), for the treatment of disease states or conditions mediated by cyclin dependent kinases and/or glycogen synthase kinase-3, including cancers.

Abstract: This document relates to conjugates of TNF inhibitors or derivatives thereof and functionalized (e.g., mono- or bi-functional) polymers (e.g., polyethylene glycol and related polymers) as well as methods and materials for making and using such conjugates.